hotspot -WSS

hotspot

author：fashion 2025-10-01 11:46:23 - browse：98483

Japanese drugmaker Eisai said Tuesday that Ivan Cheung, chairman of its U.S. operations and global head of its Alzheimer’s disease unit, will retire at the end of the month. The surprise announcement comes just days after Eisai won final approval in the U.S. for its Alzheimer’s drug Leqembi.

Cheung will be replaced in his capacity as head of the Alzheimer’s unit by his brother-in-law Keisuke Naito, 34, who is currently chief ecosystem officer and chief strategy officer. He is also the son of Eisai CEO Haruo Naito.

Tatsuyuki Yasuno, current chief financial officer, will replace Cheung as head of Eisai’s U.S. unit.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Fentanyl is making it harder to start addiction treatment

WSS

White House Covid adviser calls on docs to combat misinformation

Study finds gene variants tied to breast cancer risk in Black women

Grad students accuse University of California of wage theft

People with substance use disorder deserve online privacy

Fed up with FDA, ALS advocates consider a take

Cue Health, Covid

focus

hotspot

Wikipedia

Drug repurposing or repositioning? The language matters

FDA poised to publish guidelines for clinical trial diversity

Heart attack and stroke risk calculators need revising

FDA poised to publish guidelines for clinical trial diversity

Supreme Court strikes down use of affirmative action

People with substance use disorder deserve online privacy

Guidelines to prevent youth baseball injuries need more muscle

What happened to the House vote on health price transparency?

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Chamber of Commerce, DOJ clash in court over drug prices

focus

Covid’s new normal has set in amid another rise in cases

Investigation reveals sickle cell patients pressured into sterilizations

Transgender sports debate: Physicians say bans are health issue

FDA weighs limits of animal data in assessing artificial wombs

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Listen: A conversation with researcher Kevin Esvelt on biosecurity

knowledge

entertainment

hotspot

Wikipedia